LitAlert ~~

    • Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy.
    • Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor JC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann W.
    • JNCI Cancer Spectr. 2019 Nov 9; pkz085. doi: 10.1093/jncics/pkz085. eCollection 2019 Nov.
    • Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
    • Dowson CB, Stewart C, O'Sullivan S, Pachter N, Schofield L, Cohen PA.
    • Int J Gynecol Cancer. 2019 Nov 7. pii: ijgc-2019-000540. doi: 10.1136/ijgc-2019-000540. [Epub ahead of print]
    • Study: Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer.
    • [No author given.]
    • FORCE. XRAYS. 2019 Nov 5.

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    • The Expression Level of BRCA2 and Its Changes during Chemotherapy in Patients with Different Pathological Types of Mammary Cancer.
    • Huang Y, Luo M, Huang J, Huang S, Wei L, Zhang Y, Zhang Z.
    • Iran J Public Health. 2019 Sep;48(9):1654-1662.